Pivotal role of mTOR signaling in hepatocellular carcinoma.
暂无分享,去创建一个
Derek Y. Chiang | M. Meyerson | V. Mazzaferro | A. Ramos | S. Friedman | J. Bruix | J. Llovet | J. Martignetti | C. Battiston | Clara Alsinet | S. Waxman | Y. Hoshida | S. Thung | P. Newell | A. Villanueva | M. Solé | M. Schwartz | S. Roayaie | M. Fiel | B. Mínguez | V. Tovar | S. Toffanin | S. Van Laarhoven | Steven Yea | J. Peix | Analisa Di Feo | S. Yea | M. Fiel
[1] J. Bruix,et al. Molecular targeted therapies in hepatocellular carcinoma , 2008, Hepatology.
[2] Derek Y. Chiang,et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. , 2008, Cancer research.
[3] Dieter Häussinger,et al. Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.
[4] B. Daniele,et al. Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma , 2008 .
[5] Joseph Gera,et al. mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor. , 2007, Cancer research.
[6] E. Lander,et al. Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma , 2007, Proceedings of the National Academy of Sciences.
[7] Derek Y. Chiang,et al. Characterizing the cancer genome in lung adenocarcinoma , 2007, Nature.
[8] T. Griffin,et al. PRR5, a Novel Component of mTOR Complex 2, Regulates Platelet-derived Growth Factor Receptor β Expression and Signaling* , 2007, Journal of Biological Chemistry.
[9] P. Pandolfi,et al. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas , 2007, Nature Medicine.
[10] J. Dufour,et al. Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. , 2007, Journal of hepatology.
[11] D. Sabatini,et al. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. , 2007, Blood.
[12] V. Mazzaferro,et al. Genome‐wide molecular profiles of HCV‐induced dysplasia and hepatocellular carcinoma , 2007, Hepatology.
[13] H. Clevers,et al. Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer , 2007, Oncogene.
[14] K. Schmid,et al. Mammalian Target of Rapamycin Pathway Activity in Hepatocellular Carcinomas of Patients Undergoing Liver Transplantation , 2007, Transplantation.
[15] Derek Y. Chiang,et al. Genomics and signaling pathways in hepatocellular carcinoma. , 2007, Seminars in liver disease.
[16] V. Mazzaferro,et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. , 2006, Gastroenterology.
[17] J. Llovet,et al. Systematic review: evidence‐based management of hepatocellular carcinoma – an updated analysis of randomized controlled trials , 2006, Alimentary pharmacology & therapeutics.
[18] F Kanai,et al. Absence of PIK3CA hotspot mutations in hepatocellular carcinoma in Japanese patients , 2006, Oncogene.
[19] J. Mesirov,et al. GenePattern 2.0 , 2006, Nature Genetics.
[20] Yiling Lu,et al. Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery , 2005, Nature Reviews Drug Discovery.
[21] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[22] S. Luo,et al. Expression of albumin, IGF-1, IGFBP-3 in tumor tissues and adjacent non-tumor tissues of hepatocellular carcinoma patients with cirrhosis. , 2005, World journal of gastroenterology.
[23] P. Neuhaus,et al. Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth. , 2005, World journal of gastroenterology.
[24] Suk Woo Nam,et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas , 2005, Oncogene.
[25] M. Torbenson,et al. mTOR and P70 S6 Kinase Expression in Primary Liver Neoplasms , 2004, Clinical Cancer Research.
[26] Jian Yu,et al. Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis. , 2004, World journal of gastroenterology.
[27] Francesco Donato,et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. , 2004, Gastroenterology.
[28] S. Thorgeirsson,et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling , 2004, Hepatology.
[29] M. Bjornsti,et al. The tor pathway: a target for cancer therapy , 2004, Nature Reviews Cancer.
[30] M. Colombo,et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. , 2004, Gastroenterology.
[31] M. Tai,et al. Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma , 2003, Cancer.
[32] S. Kawasaki,et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. , 2003, Journal of hepatology.
[33] C. Sawyers,et al. The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.
[34] Steven C. Lawlor,et al. GenMAPP, a new tool for viewing and analyzing microarray data on biological pathways , 2002, Nature Genetics.
[35] Yusuke Nakamura,et al. Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway , 2001, Oncogene.
[36] R. Prywes,et al. Activation of the c-fos enhancer by the Erk MAP kinase pathway through two sequence elements: the c-fos AP-1 and p62TCF sites , 2000, Oncogene.
[37] Chien-Jen Chen,et al. PTEN/MMAC1 mutations in hepatocellular carcinomas , 1999, Oncogene.
[38] J. Hartley,et al. Isolation of transforming murine leukemia viruses from mice with a high incidence of spontaneous lymphoma. , 1977, Proceedings of the National Academy of Sciences of the United States of America.